Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis

Autor:	Rui Zhao, Qianyi Wan, Haitao Xiao, Ying Cen, Ruolin Liu, Xuewen Xu
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Cancer Research medicine.medical_specialty Population Review Biologics Inflammatory bowel disease Non-melanoma skin cancer Internal medicine Psoriasis Genetics medicine Rheumatoid arthritis education RC254-282 education.field_of_study QH573-671 business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Squamous cell skin cancer medicine.disease Basal cell epithelioma Oncology Relative risk Skin cancer business Cytology
Zdroj:	Cancer Cell International, Vol 21, Iss 1, Pp 1-17 (2021) Cancer Cell International
ISSN:	1475-2867
Popis:	Background Most previous studies compared the risk for non-melanoma skin cancer (NMSC) in biologic-treated common inflammatory diseases with the general population. Whether the increased NMSC risk is caused by the disease itself, the biologics, or both remains unknown. Methods We systematically searched PubMed, Embase, Medline, Web of Science, and Cochrane Library from inception to May 2021. Studies were included if they assessed the risk of NMSC for rheumatoid arthritis (RA), inflammatory bowel disease (IBD), or psoriasis patients treated with biologics compared with patients not receiving biologics. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using the fixed- or random-effects model. Results The current meta-analysis included 12 studies. Compared with patients with the inflammatory disease without biologics, patients receiving biological therapy were associated with an increased risk for NMSC (RR 1.25, 95% CI 1.14 to 1.37), especially in patients with RA (RR 1.24, 95% CI 1.13 to 1.36) and psoriasis (RR 1.28, 95% CI 1.07 to 1.52), but not in patients with IBD (RR 1.49, 95% CI 0.46 to 4.91). The risks for squamous cell skin cancer and basal cell skin cancer were both increased for patients receiving biologics. However, the risk of NMSC did not increase in patients treated with biologics less than 2 years. Conclusions Current evidence suggests that increased risk of NMSC was identified in RA and psoriasis treated with biologics compared with patients not receiving biologics, but not in patients with IBD. The inner cause for the increased risk of NMSC in IBD patients should be further discussed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e558c4ab0085fb31ac85a145330adf https://doaj.org/article/22b616d7155c448da005b4c2b2a7582e Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.